Huawei focuses AI on cervical cancer

Huawei Technologies has had time to develop new business lines while fighting off the US government, apparently. The company announced this week its joint venture with Kingmed Diagnostics, a third-party medical testing institution, had been “making progress” in using AI to help with diagnosis of cervical cancer.

Using Huawei’s AI development platform ModelArts, the screening model is able to use the diagnostic criteria of pathologists to assist the screening of cervical cancer. On the basis of a rejection rate higher than 60%, the model can achieve 99% correction rate of the interpretation of negative films and 99.9% of positive lesions.

The new model can help fill in the gap between the limited number of pathologists and an estimated 350 million female women eligible to be examined. The traditional screening process requires pathologists to read the film under microscopes one by one, with judgments based on the human eye and personal experience, which requires a training process of around 10 years. There are only 20,000 registered pathologists in China, however, and another 80,000 to 100,000 are needed.

Read more in Chinese.